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Epstein Barr virus (EBV) is a gamma herpesvirus that is implicated in the development of 
nasopharyngeal carcinoma (NPC) and other human malignancies of diverse tissue 
origins. The control of natural EBV infection is mediated by a vigorous cytotoxic CD8+ 
T-lymphocyte response targeting viral peptides presented on the surface of infected cells 
in association with MHC class I. In NPC cells, a principle EBV gene product with 
oncogenic activity is latent membrane protein (LMP1).  Whilst an LMP1-specific CD8+ 
T cell response is detectable in healthy individuals, it is often undetectable in NPC 
patients.   In this study, we provide a mechanistic insight into why the LMP1 associated 
with NPC cells but not human B-lymphocytes is poorly recognised by the human 
immune system.   We show that LMP1 derived from NPC cells contains a number of 
point mutations that are predicted to effect cytotoxic T-cell epitopes.  We analyse the 
impact of these mutations by studying a well-characterised HLA-A*0201 restricted 
epitope YLLEMLWRL that is found to have two amino acid substitutions in NPC.  By 
utilising a unique T cell receptor-like monoclonal antibody combined with LMP1 specific 
cytotoxic T cell lines, we demonstrate that the NPC associated mutations in LMP1 result 
in a severe impairment in antigen presentation.  We also show that the mutated form of 
LMP1 retains its functionality compared to the B-lymphocyte form of the protein.  The 
results of this study highlight how sequence variations in EBV gene products help virus 
infected tumour cells escape immune recognition. This has important implications for the 
design of subunit vaccines and adoptive immunotherapies for the treatment of EBV-
associated malignancies like NPC.  
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Chapter 1: ITRODUCTIO 
 
Epstein-Barr virus (EBV) is a gamma herpes virus that infects 95% of the human 
population and is strongly associated with nasopharyngeal carcinoma (NPC). NPC is a 
cancer that originates in the nasopharynx of the throat (Vasef et al., 1997) and initially 
presents as small lesions or ulcerations that are difficult to detect. NPC is endemic in 
Southern China and Southeast Asia, where several genetic and environmental 
characteristics have been proposed as risk factors. Expedient diagnosis and effective 
treatment are essential for NPC management as the survival rate decreases rapidly with 
the progress of the cancer (Chang et al., 2004, DeNittis et al., 2004).  
 
The main EBV oncogenic protein is the latent membrane protein (LMP1), which usually 
elicits a weak or undetectable CD8+ T cell response in NPC patients (Li et al., 2007). A 
lower molecular weight variant of LMP1 (NPC LMP1) has been characterised in NPC 
(Cheung et al., 1999; Lin et al., 2004). This study aims to characterise at a molecular 
level the antigen processing and presentation of NPC LMP1 on HLA class I using a novel 
TCR-like antibody specific for an HLA-A2-restricted LMP1 epitope. Our results will 
ascertain how changes in the sequence of LMP1 affect its antigen processing and 
presentation and how this impacts upon the subsequent adaptive immune response. 
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Chapter 2: LITERATIVE REVIEW 
 
2.1 asopharyngeal Carcinoma 
2.1.1 Description of nasopharyngeal carcinoma (PC) 
Nasopharyngeal carcinoma (NPC) refers to a form of cancer that originates in the 
nasopharynx of the throat. Three histological types of NPC cells have been described by 
the World Health Organization (WHO): keratinising, nonkeratinising and 
undifferentiated NPC. Nonkeratinising NPC is strongly associated with Epstein-Barr 
virus (EBV) (Vasef et al., 1997) and is characterised by a massive infiltration of 
lymphocytes in the tumour tissue. Detection of lymphocytes in keratinising NPC is far 
less common.  
 
NPC is divided into four stages: Stage I: The cancer is limited to the nasopharynx; Stage 
II: The cancer has spread to the nasal cavity or the soft tissues of the throat. At this stage, 
the cancer may also have spread to the lymph nodes on one side of the neck; Stage III: 
The cancer has spread to the lymph nodes on both sides of the neck and the associated 
bones; Stage IV: The cancer has spread to the facial nerves or lower portion of the throat, 
the skull or the bones around the eyes. At this stage, the cancer is likely to have 
metastatised to other parts of the body. 
 
2.1.2 Geographical distribution of PC 
NPC is rare in most parts of the world, particularly in Europe and North America, having 
a disease incidence of lower than 1 per 100 000 person-years (Ferlay et al., 2001). 
However, NPC is endemic in Southern China, with an incidence rate of 25 per 100 000 
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person-years in Guangzhou (Yu et al., 2002). In Singapore, NPC is the fifth most 
common cancer in men and eighth most common cancer in women. 
 
 
Fig. 2.1. Geographical distribution of PC incidence rates (calculated per 100 000 
person-years) for male patients. (Adapted from Busson et al., 2004)  
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2.1.3 Environmental and genetic factors implicated in PC 
EBV has a strong association with NPC (Andersson-Anvret et al., 1977). Besides EBV, 
several environmental and genetic cofactors are thought to play a supporting role in the 
development of NPC. Specific dietary habits appear to increase the risk of NPC in 
endemic countries. These include salted fish in Southern China (Yu et al., 2002), and 
salted meat and eggs in Malaysia (Armstrong et al., 1998). Poor ventilation in homes also 
predisposes people to NPC (Jeannel. et al., 1990). A recent prospective cohort study 
based in Singapore indicated that long-term smoking was a risk factor in development of 
NPC (Friborg et al., 2007). 
 
Interestingly, it has been observed that lifestyle changes do not significantly lower the 
risk of NPC, indicating that genetic factors interact with environmental factors in creating 
an overall high-risk profile. In this aspect, Southern Chinese workers who migrate 
frequently also have a high risk of NPC, although the risk is lower than in their country of 
origin. 
 
The significance of specific genotypes in disease aetiology has been a major focus of 
NPC studies. Several putative genes of high penetrance have been proposed. These 
include a predisposition locus on chromosome 4p (Feng et al., 2002) and 3p21 
(Xiong et al., 2004); and polymorphisms in heat shock protein 70 (Jalbout et al., 2003), 
IgA receptor (Hirunsatit et al., 2003), IL-1β (Zhu et al., 2008) and IL-8 (Wei et al., 2007, 
Ben et al., 2007). 
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2.1.4 Diagnosis and treatment of PC 
The initial presentation of NPC is generally observed as small lesions at the back of the 
nasopharynx and diagnosis is based on histological analysis of patient biopsies. To 
establish the stage of NPC, magnetic resonance imaging and computerised tomography 
are performed to determine the tumour size, lymph node involvement and metastasis to 
bones and surrounding tissue.  
 
Radiotherapy is the current treatment of choice for NPC. Although the response to 
radiotherapy is more favourable in NPC compared to other forms of cancer (Altun et al., 
1995, Chow et al., 1997), this effect is largely dependent on the tumour type and stage. 
Keratinising NPC is more resistant to radiotherapy than nonkeratinising NPC. The 
likelihood of locoregional recurrence also increases with advanced stages of NPC. 
Combined radio-chemotherapy may improve the chances of survival in advanced stages 
(Al-Sarraf et al., 1997). In stages I and II NPC, the 5 year survival rate is 72% to 90%, 
but decreases to 55% in stage III and further falls to 30% in stage IV (Chang et al., 2004, 
DeNittis et al., 2004).  
 
Unfortunately, the diagnosis of NPC is usually made at an advanced stage when disease 
relapse rates can reach 82% even with combined radio-chemotherapy (Cheng et al., 
2000). The diagnosis process is difficult because of the non-specific symptoms presented 
at early stages of the disease and the difficulty in making a histological diagnosis of a 
patient biopsy (Lee et al., 1997). Therefore, there is a need for better diagnostic markers 
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based on the molecular phenotype of an NPC cell and specific therapy that can target 
NPC tissue in advanced stages of the disease. 
 
2.2 Epstein-Barr virus 
2.2.1 Classification 
Epstein-Barr virus belongs to the herpes virus family and is classified as a gamma-1 
herpes virus, which infects only primates. A hallmark of gamma-1 herpes viruses is their 
ability to manipulate the physiology of B cells such that the virus can persist in the B cell 
compartment of an infected host.  
 
2.2.2 Structure of Epstein-Barr virus 
EBV contains a linear, double-stranded 184kb DNA genome wrapped in a toroid-shaped 
protein core. The genome contains short and long unique sequence domains (US and UL) 
that contain most of the coding capacity of the virus. When EBV infects a cell, the linear 
termini of the DNA join intracellularly to form an episome that persists indefinitely in the 
infected cell (Lindahl et al., 1976).  
 
 7 
2.2.3 Transmission of Epstein-Barr virus 
EBV is ubiquitous, being present in more than 90% of the human population (Henle et 
al., 1969). It is transmitted through contact with cervical and oral secretions from an 
infected person (Hoagland, 1955). Primary EBV infection usually occurs at an early age 
and is clinically asymptomatic. However, if infection is delayed until adolescence, a self-
limiting lymphoproliferative disorder known as infectious mononucleosis results.  
 
There was early speculation that EBV first targeted oropharyngeal epithelial cells during 
transmission of the virus. In support of this proposition, it has been established that EBV 
is able to infect and replicate in selected epithelial cell types, such as the nasopharyngeal 
and gastric epithelial cells. In contrast, more recent reports have shown that infection of 
EBV may bypass the epithelial layer as EBV was not detected in the tonsillar epithelium 
of patients with infectious mononucleosis (Karajannis et al., 1997). However, despite the 
controversy surrounding the initial entry of EBV, it is certain that EBV establishes stable 
infection primarily in B cells in a healthy human host. 
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2.3 The infection cycle of Epstein-Barr virus 
2.3.1 Stable infection of B cells with Epstein-Barr virus 
EBV establishes a persistent infection of B cells in an individual, where numbers of 
latently infected B cells number between 0.5 to 50 per million B cells (Khan et al., 1996). 
The virus enters the B cell through the binding of the viral envelope glycoprotein 
gp350/220 with the B cell surface molecule CD21, a complement receptor that associates 
with CD19 and CD81 (Fingeroth et al., 1984). Upon binding of gp350/220 to the two N-
terminal extracellular domains of CD21 (Young et al., 2007), CD21 aggregates and EBV 
is internalised into the B cell (Carel et al., 1990). This fusion process is facilitated by a 
separate interaction between HLA class II and another virus glycoprotein, gp42 (Li et al., 
1997).  
 
2.3.2 Latent infection in the memory B cell compartment 
Depending on the location of the infected B cell, EBV exhibits two different effects on 
the cell physiology. If the infected cell is located within the nasopharyngeal lymphoid 
system, the virus enters the lytic cycle and actively replicates itself (Gerber et al., 1972). 
During lytic infection, approximately 80 viral proteins, including DNA replication factors 
and viral capsid proteins (reviewed by Kutok and Wang, 2006). The infectious virus buds 
off and is released upon lysis of the infected cell into the follicular mantle of the 
oropharyngeal cavity, where it can be transmitted to a second individual. On the other 
hand, if an EBV-infected B cell is in the peripheral circulation, the virus enters latency 
where no infectious particles are produced and the expression of viral proteins is highly 
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restricted. The control from the lytic to latent cycle is mediated by the BZLF1 and 
BRLF1 proteins (reviewed by Kutok and Wang, 2006). 
 
In latency, only six Epstein-Barr virus nuclear antigens (EBNA), three latent membrane 
proteins (LMP) and two small non-polyadenylated Epstein-Barr virus-encoded small 
RNAs (EBERs) are expressed. There are three patterns of latent gene expression 
described in the literature (Table 2.1). Typically, the infected B cell passes through 
Latency III, II and I (in order) and remains immunologically undetectable by circulating 
CD8+ T cells. 
 
Table 2.1. Latency transcription programmes initiated by EBV 
Programme Genes expressed Function 
Latency III EBNA1-6, LMP1, LMP2A, 2B, 
EBERs 
Promotes growth and proliferation of a 
resting B cell. 
Latency II EBNA1, LMP1, LMP2A, 
EBERs 
Maintains the survival of the infected 
cell and/or initiates development of the 
B cell into a memory B cell. 
Latency I/0 LMP2A Allows the virus to persist quiescently 
in the memory B cell. 
 
2.3.3 Latent infection in the epithelial cell compartment 
Infection of non-B cells by EBV is associated with the development of a number of 
human carcinomas with diverse tissue origins (reviewed in Young and Rickinson, 2004). 
In NPC, the virus infects the epithelial cells of the nasopharyngeal tract and turns on the 
latency II programme. Although it has been established that CD21 is the receptor 
triggering EBV entry into B cells, there is some controversy regarding the entry of EBV 
into epithelial cells. Initial evidence pointed to viral entry through a low surface 
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expression of CD21 on NPC cells (Billaud et al., 1989). However, a recent study did not 
detect expression of CD21 on NPC cells by immunohistochemistry (Burgos et al., 2000). 
As the epithelial cells cannot differentiate into memory B cells, the virus cannot turn off 
the latency II programme and continues to express viral proteins such as LMP1. LMP1 
constantly activates the NFκB pathway, resulting in cell survival and growth, which 
could induce the formation of a tumour mass if left unchecked by the immune system. 
 
2.4 Latent membrane protein 1 in the modulation of CD8
+
 T cell response 
2.4.1 Latent membrane protein 1 
LMP1 is a 60kDa transmembrane protein that is expressed by EBV during the latent 
cycle. LMP1 is of great interest because it is considered the main oncoprotein expressed 
by EBV. In vitro, LMP1 can transform rodent fibroblasts (Wang et al., 1985, Moorthy et 
al., 1993) and enables anchorage-dependent growth of Balb 3T3 cells in soft agar 
(Baichwal et al., 1988). LMP1-transfected rodent cells are tumourigenic in nude mice 
(Wang et al., 1985) and the expression of LMP1 in transgenic mice increases the 
incidence of lymphoma by three times (Thornburg et al., 2006). LMP1 is expressed in 
65% of NPCs (Fåhraeus et al., 1988, Young et al., 1988). In the remaining 35% of 
LMP1-nonexpressing NPCs, the transactivator of the LMP1-encoding BNLF-1 gene is 
highly methylated, leading to silencing of the gene (Hu et al., 1991). 
 LMP1 is functionally homologous to CD40 and can substitute completely for CD40 
signalling in transgenic mice (Rastelli et al., 2008). Constitutive signalling of CD40 
promotes cell transformation and neoplastic growth and may account for the oncogenic 
properties of LMP1 (Baxendale et al., 2005). There are two main signalling regions 
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located at the cytoplasmic termini of LMP1, C-terminal activating region (CTAR) 1 and 
2. CTAR 1 and 2 have PXQXT motifs, which bind the adaptor proteins TNFR-associated 
factors (TRAFs) (Devergne et al., 1996, Franken et al., 1996). LMP1 aggregates through 
its transmembrane domains and binds TRAFs constitutively (Devergne et al., 1996, 
Franken et al., 1996), leading to activation of the family of NFκB transcription factors 
(Paine et al., 1995, Miller et al., 1998) that influence expression of a repertoire of 
proteins in the cell. In particular, the activation of the NFκB and JNK pathways leads to 
an inhibition of apoptosis and increase in proliferation. 
 
Fig. 2.2. Signalling of LMP1. The cytoplasmic tail of LMP1 contains the PXQXT motif 
which binds TRAFs to activate the NFκB pathway. Binding of Janus kinase 3 (JAK3) to 
LMP1 also activates the c-Jun N-terminal kinase (JNK) pathway. Both pathways result in 
inhibition of apoptosis and an increase in proliferation of the infected B cells. (Adapted 
from David A. Thorley-Lawson (2001) ature Rev Immunology. 1:75-82) 
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2.4.2 The antigen processing pathway 
Antigen processing is a pathway through which an infected cell processes viral proteins 
for presentation to circulating CD8+ T cells, allowing them to destroy the infected cell. 
Viral proteins are degraded in the cytosol by the immunoproteasome and the resultant 
peptides transported to the endoplasmic reticulum via the Transporter Associated with 
Antigen Processing (TAP). The peptides are then loaded onto newly synthesised HLA 
class I molecules in the ER for transport to the surface of the cell. 
 
The HLA class I molecule is a heterotrimer, consisting of the noncovalent association of 
a 45kDa heavy chain, a 12kDa β2-microglobulin unit and a peptide. HLA-A2 is one of 
the most immunodominant and best studied HLA antigens. The HLA-A2 supertype, 
which covers approximately 50% of the worldwide human population, consists of the 
subtypes A*0201, A*0202, A*0203, A*0204, A*0205, A*0206, A*0207, A*6802 and 
A*6901 (del Guercio et al., 1995; reviewed in Sette and Sidney, 1998). Crystallographic 
analysis of the HLA-A2 structure shows that it is made up of eight antiparallel β-sheets 
topped by α-helices (Bjorkman et al., 1987). The peptide-binding cleft is located between 
the α-helices and binds peptides processed by the MHC class I loading pathway 
(Bjorkman et al., 1987). The T cell receptor (TCR) binds diagonally across the peptide-
binding cleft, and recognises the peptide and components of HLA-A2 in a topographic-
specific manner (Garboczi et al., 1996). 
 
Upon binding of the TCR to the HLA class I molecule, together with concurrent co-
stimulus, the antigen-specific CD8+ T cell is activated to kill the infected cell. The T cell 
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releases two cytolysins, perforin and granulysin, which create pores in the membrane of 
the infected cells to induce lysis and eventual cell death. The CD8+ T cell also expresses 
Fas ligand (FasL), which binds to Fas on the infected cell. Trimerisation of Fas-FasL 
activates a caspase cascade that leads to cell death. To increase the magnitude of the 
immune response, CD8+ T cells are activated to undergo clonal expansion through the 
autocrine release of IL-2, increasing the amount of antigen-specific T cells that can 
eliminate the infected cells. 
 
2.4.3 The anti-LMP1 CD8
+
 T cell response 
CD8+ T cell activity is important for controlling EBV spread by recognising peptides 
presented on infected cells and initiating cytotoxic killing of the cells. 55 to 60% of the 
healthy Caucasian population mounts LMP1-specific T cell responses against EBV 
(Khanna et al., 1998) and these responses are often restricted through HLA-A2 alleles 
(Meij et al .2002). However, NPC develops in immunocompetent individuals, indicating 
that EBV-infected tumour cells are able to escape immunosurveillance by circulating 
CD8+ T cells.  
 
There are two explanations that have been proposed to account for this lack of immune 
response: immune suppression and immune avoidance. In immune suppression, EBV 
alters the cell physiology to create an immunosuppressive network of molecules that 
subvert the immune response. In this aspect, EBV encodes a homolog of the inhibitory 
cytokine, IL-10, during the initial phase of infection (Hayes et al., 1999). IL-10 decreases 
the activity of antigen presenting cells and also decreases TH1 responses. It has also been 
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demonstrated that antigen processing of LMP1 in infected cells can stimulate high levels 
of IL-10 production by CD4+ T cells (Marshall et al., 2003), which is a process 
reminiscent of T regulatory cell induction. In doing so, it manipulates the immune system 
such that the LMP1-specific CTL response is weak. Interestingly, other anti-
inflammatory molecules, such as galectin-1 (Gandi et al., 2007), have also been 
implicated in the suppression of the CTL response. 
 
In immune avoidance, the LMP1 epitopes are not presented on the infected cells due to 
alterations in their amino acid sequences. LMP1 can be presented on NPC cells and its 
four HLA-A2-restricted epitopes have been characterised, the most prominent being the 
9-mer YLLEMLWRL (Khanna et al., 1998). The epitope YLLEMLWRL is of great 
interest because it is the only HLA-A2 restricted epitope that exhibits sequence variations 
across different geographical locations. Seven variants of LMP1 have been described 
(Figure 2.4) and one particular variant, China 1 (YFLEILWRL) is closely associated with 
NPC in several studies on Southern Chinese patients (Cheung et al., 1999, Lin et al., 
2004). The two amino acid change in the epitope has been speculated to impair antigen 
presentation therefore reduce detection by circulating CD8+ T cells. 
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2.5.1 TCR-like monoclonal antibodies 
Reagents that recognise specific peptide-HLA class I immunocomplexes are valuable for 
studying antigen presentation on a cell surface. In this regard, soluble TCRs that bind 
HLA class I bound antigens have been synthesised (Holler et al., 2000), but their affinity 
is too weak to enable robust detection of the cell surface HLA-peptide complexes.  
 
Monoclonal antibodies offer several advantages over soluble TCRs in that they have 
higher affinity and stability, thus allowing for the application of biochemical techniques 
such as immunoprecipitation and immunohistochemistry. However, monoclonal 
antibodies that recognise a specific peptide presented on HLA class I have been 
notoriously hard to generate. 80% of the peptide in the HLA class I complex is buried in 
the peptide-binding groove (Rudolph et al., 2002) and is therefore inaccessible to 
interaction with other proteins. Physiologically, this has resulted in a lower binding 
energy of the HLA class I immunocomplex with the TCR as compared to other types of 
protein interactions (Willcox et al., 1999). In the case of TCR-like antibodies, it has 
increased the difficulty of generating a monoclonal antibody with specificity for the 
unique peptide presented on HLA class I. Several studies have produced such antibodies 
(Porgardor et al., 1997, Bernardeau et al., 2005, Wittman et al., 2006), and these 
antibodies have been shown to have higher affinity and stability than soluble TCRs. 
Interestingly, TCR-like antibodies make different contacts on the surface of the HLA 
class I immunocomplex compared to the TCR to achieve the same specificity (Biddison 
et al., 2003), and this difference may account for their more stable interactions with the 
HLA class I immunocomplex. TCR-like antibodies have previously been used to 
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quantitate HLA class I immunocomplexes on the surface of virus-infected cells and 
tumour cells (Porgardor et al., 1997) and to determine the optimal level of complexes 
required for CD8+ T cell activation (Bernardeau et al., 2005). 
 
2.5.2 The MHC stabilisation assay 
Assays that determine the binding of a peptide epitope on HLA class I, and by inference 
the ability of the presented peptide to elicit a CD8+ T cell response, are important for 
studying antigen presentation. In this regard, the MHC stabilisation assay was developed 
to define the ability of a peptide to bind to HLA-A2 (Elvin et al., 1993). Parker et al., 
(1992) demonstrated that a peptide is required for the stable folding of nascent HLA class 
I molecules prior to their display at the cell surface. T2 is a TAP-deficient cell line that 
synthesises empty HLA-A2 molecules, which have a shorter half-life due to the absence 
of a stabilising peptide (Townsend et al., 1990). These empty HLA-A2 molecules can be 
stabilised by the addition of exogenous peptides that have binding affinity for HLA-A2 
(Townsend et al., 1990; Cerundolo et al, 1991; Schumacher et al, 1990; Elliott et al, 
1991; Elvin et al, 1991). The increased stabilization is detected with a confirmation-
specific anti-HLA-A2 antibody. Consequently, the extent to which a candidate 
immunogenic peptide epitope binds HLA class I can be correlated with its ability to 
stabilise empty HLA class I molecules on the T2 cell line. In the MHC stabilisation 
assay, candidate peptides are added to the T2 cell line and the resultant stabilisation of 
HLA-A2 molecules correlated with the binding affinity of the peptide.  
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2.6 Scope of the project 
Despite the fact that individuals can mount a robust CD8+ T cell response against LMP1, 
this response is weak in NPC patients, with low frequencies of LMP1-specific CD8+ T 
cell precursors being induced. Differences in the immunogenicity of the B95-8 strain of 
LMP1 (WT LMP1) compared to the NPC-associated China 1 strain of LMP1 (NPC-
LMP1) have been implicated in the lack of LMP1-specific CD8+ T cell response in NPC 
patients.  
 
Two explanations have been offered for this observation: 
(1) LMP1-specific immunogenicity could be avoided in NPC if epitope mutations in 
NPC-LMP1 reduces antigen presentation on surface HLA class I molecules 
(Cheng et al., 1999; Lin et al., 2004). 
(2) Antigen presentation is unaffected, but the infected cell could inhibit CD8+ T cell 
activation by increasing the production of inhibitory cytokines such as IL-10 (Pai 
et al., 2007). 
 
The aim of this project is to directly address the first issue by using a TCR-like 
monoclonal antibody generated in-house, with specificity for the well-defined 
YLLEMLWRL peptide epitope (Khanna et al., 1998) presented on HLA-A*0201, to 
determine the relative levels of HLA-A2-peptide complexes presented on HLA-A*0201 
positive NPC cell lines transfected with WT LMP1 and NPC LMP1. The results of this 
study will determine if the CD8+ T cell response to LMP1 is weaker in NPC due to 
inadequate antigen processing and presentation. This would shed light on possible 
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mechanisms by which LMP1 helps EBV escape the immune response and has 
implications for the development of immunotherapy in the treatment of NPC. 
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Chapter 3: MATERIALS AD METHODS 
 
3.1 Cell lines and culture media 
The cell lines C1R A2 and T2 were obtained from ATCC. The NPC cell lines CNE1 and 
C666, together with a panel of B lymphoblastoid cell lines expressing different HLA 
types, were a kind gift from Emeritus Professor Chan Soh Ha, WHO Immunology 
Centre. CNE1, an EBV-negative NPC cell line, was transduced with a HLA-A*0201 
lentiviral vector to produce the CNE1-A2 line. All cell lines were maintained in RMPI-
1640 medium (Gibco Laboratories), supplemented with 10% (v/v) foetal bovine serum 
(FBS) from Sigma, 1% penicillin (Sigma) and 1% streptomycin (Sigma) and grown in 
5% CO2 at 37°C. 
 
3.2 Peptides 
WT LMP1 (YLLEMLWRL), NPC LMP1 (YFLEILWRL), M1 (GILGFVFTL) and 
Influenza A nucleoprotein (ELRSRYWAI) peptides were purchased from Mimotopes.  
 
3.3 Generation of a TCR-like monoclonal antibody 
3.3.1 Production of the HLA-A2 monomers 
HLA-A2 monomers (based on the HLA-A*0201 sequence) were synthesised as described 
previously (Parker et al. 1992). Briefly, a HLA-A*0201 positive Bone Marrow Donor 
(BMD) cell line was chosen according to the BMD database. Total RNA was extracted 
from the cells and cDNAs were synthesised using the QIAGEN One Step RT-PCR Kit 
(Qiagen), with primers designed to amplify the entire coding sequence of the HLA heavy 
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chain. The resultant PCR products were cloned into the pET30-BirA vector and 
transformed into E. coli BL21 cells. The isolated inclusion bodies were collected from 
the BL21 cells and refolded with β2 microglobulin and LMP1 peptide to form a HLA-A2 
monomer. The refolded monomers were dialysed against 20mM Tris and purified using 
anion exchange and gel filtration on Fast Protein Liquid Chromatography (FPLC).  
 
3.3.2 Immunisation of mice and generation of hybridomas 
6-7 week old BALB/c female mice were inoculated subcutaneously with 25µg of HLA-
A2 monomers emulsified in 500µl of complete Freund's adjuvant (Sigma). Booster 
injections were given on day 21 and 35 with the immunogen in 500µl incomplete 
Freund's adjuvant (Sigma) intraperitoneally. On day 45, the spleens were aseptically 
harvested. For immunomagnetic selection, the isolated splenocytes were incubated with 
100µg of biotinylated HLA-A2 monomer for 20min at 4°C, followed by 100µl of anti-
biotin MACS beads for 20min at 4°C. The MACS-isolated cells were fused with NS1 
myeloma cells in polyethylene glycol. Fused cells were seeded in twelve flat-bottom 96-
well plates (Nunc) and grown in hypoxanthine thymidine aminopterin (HAT) selective 
medium.  
 
3.3.3 Screening of hybridoma clones 
1 x 106 WT LMP1 peptide-pulsed C1R A2 cells were incubated with the relevant 
hybridoma supernatant at 4°C for 30 min. To detect the binding of antibody, cells were 
incubated with 0.5µl of 10µg/ml Alexa Fluor 488 goat anti-mouse IgG (Invitrogen) at 
room temperature for 20min. Between each incubation step, cells were washed twice with 
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1×PBS. After the final wash step, cells were resuspended in 500µl of 2.5% 
paraformaldehyde fixative. C1R A2 cells pulsed with M1 peptide served as negative 
control. The cells were acquired and analysed using Cyan ADP (DakoCytomation). One 
clone, #230, was selected for antibody production. 
 
3.3.4 Purification of hybridoma culture supernatant 
#230 cells were grown up to a total volume of 1L. The hybridoma culture supernatant 
was extracted and filtered with a 0.2µm filter (Nalgene). The filtered supernatant was run 
through a FPLC column utilising protein G sepharose beads (GE Healthcare). The #230 
antibody was eluted with 0.1M glycine (pH 2.7) and dialysed against 1×PBS using the 
Slide-A-Lyzer® Dialysis Cassette (Pierce Biotechnology). To check the purity of the 
eluted antibody, 30µl of the eluted fraction was run on a 15% SDS-PAGE and stained 
with Coomassie blue. The antibody concentration of the purified culture supernatant was 
assayed for using the Coomassie Plus Protein Assay Reagent (Pierce Biotechnology). The 
purified culture supernatant was stored at 4°C. 
 
3.4 Expression of the WT LMP1 and PC LMP1 protein in CE1-A2 cells 
3.4.1 Cloning of the WT LMP1 and PC LMP1 genes 
DNA was extracted from the B lymphoblastoid cell line, CF986 and NPC cell line, C666 
using the Dneasy blood and tissue kit (Qiagen). The WT LMP1 and NPC LMP1 genes 
were amplified from CF986 and C666 respectively using Pfu polymerase (Promega). The 
primers and cycling conditions are shown in Tables 3.1 and 3.2. 
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Table 3.1. Primers used to amplify the LMP1 gene 
Primer name Primer sequence (5’3’) 
WT LMP1 forward primer CACCATGGAACACGACCTTGAGAG 
NPC LMP1 forward primer CACCATGGAACGCGACCTTGAGAG 
LMP1 reverse primer TTAGTCATAGTAGCTTAGCTGAACTGG 
 
Table 3.2. Cycling conditions used in amplification of LMP1 gene 
Cycle Temperature (ºC) Duration (min) 
Initial denaturation 95 2 
Denaturation 94 1 
Annealing 50 0.5 
Extension 72 1 
Final extension 72 5 
 
The 1.5kb PCR product was visualised on a 1% agarose gel and gel-purified using the 
Qiaquick gel extraction kit (Qiagen). The PCR product was cloned into the pLenti6 
vector using the pLenti6/V5 Directional TOPO Cloning Kit (Invitrogen) according to the 
manufacturer’s instructions. The lentiviral plasmids were purified using the Endofree 
Maxiprep kit (Qiagen) for use in the infection of CNE1-A2 cells.  
 
3.4.2 Lentiviral transfection of CE1-A2 cells with WT LMP1 and PC LMP1 
The lentiviral plasmid was packaged into viral particles by co-transfection with pCMV∆ 
8.91 and pMD2G (kind gifts from D. Trono, EPFL, Lausanne, Switzerland) into 293T 
cells using calcium phosphate precipitation. Viral supernatant was collected 48hr after 
transfection and filtered through 0.45µm filter (Millipore). CNE1-A2 cells were infected 




3.4.3 Detection of LMP1 transcripts by RT PCR 
RNA from 1 x 106 transfected cells was extracted using the High Pure RNA Isolation kit 
(Roche) and 1µg RNA amplified by RT PCR using the appropriate primers. β-actin was 
used as internal control. 
 
3.4.4 Detection of LMP1 expression by western blotting 
2 x 106 transfected cells were lysed in 50µl non-denaturing lysis buffer (600µl TBS 
containing 0.5% NP-40) supplemented with protease inhibitors (Roche) at 4°C for 30 
min. 40µl of the lysate was loaded per well for evaluation by 10% glycine SDS 
polyacrylamide gel. After gel electrophoresis, the proteins on the gel were 
electrophoretically transferred to nitrocellulose membranes (Bio-Rad) using a wet 
transfer apparatus (Bio-Rad). The membranes were blocked with 5% (w/v) non-fat milk 
in PBST (1×PBS containing 0.2% Tween-20) at 4°C overnight. The membranes were 
exposed to CS1-4 antibody cocktail from Imagenex (1:300 dilution) at 4°C overnight, 
followed by incubation with HRP-conjugated goat anti-mouse IgG (Pierce) at room 
temperature for 1h. The membranes were washed with PBST in between each step. 
Antibody-reactive bands were identified by chemiluminescence-based detection using 
Western Lightning Chemiluminescence Reagent (Perkin-Elmer Life Sciences). Actin was 
used as loading control. 
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3.5 Detection of antigen presentation on transfected cells 
3.5.1 Metabolic labelling and detection of LMP1 peptide-HLA-A2 complexes on 
transfected cells 
20 x 106 cells were incubated with 5ml methionine-free RPMI medium at 37°C for 1h, 
followed by incubation with 0.5mCi/ml 35S-methionine (Amersham) for 1h. The cells 
were washed with 1×PBS and lysed in non-denaturing lysis buffer, supplemented with 
protease inhibitors (Roche). The lysate was incubated with 5µg of #230 for 16h and 
immunoprecipitated using protein G sepharose beads (Sigma), followed by evaluation 
with 10% SDS-PAGE. The gel was dried and the bands visualised by autoradiography 
using photographic film (Kodak) at -70°C. Actin was used as loading control. 
 
3.5.2 MHC stabilisation assay 
1 x 106 T2 cells suspended in 1ml of culture media were incubated with relevant peptide 
(to a final concentration of 10µM) at 37°C and 5% CO2 for 18h. After incubation, the 
cells were washed three times in 1×PBS to remove traces of excess peptide and prepared 
for evaluation by flow cytometry. 
 
3.5.3 Detection of HLA-A2-peptide complexes on BLCLs 
1 x 106 cells were pulsed with increasing concentrations of peptide, ranging from 1nM to 
10 000nM (final concentration) and incubated with 0.5µg of #230 at 4°C for 30 min, 
followed by detection with 0.5µl of 10µg/ml Alexa Fluor 647 goat anti-mouse IgG 
(Invitrogen) and analysis by flow cytometry. 
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3.5.4 Detection of molecules involved in antigen presentation and co-stimulation 
1 x 106 cells were incubated with the relevant antibody at 4°C for 30 min. To detect the 
binding of antibody, cells were incubated with 0.5µl of 10µg/ml Alexa Fluor 488 goat 
anti-mouse IgG (Invitrogen) or Alexa Fluor 647 goat anti-mouse IgG (Invitrogen) at 
room temperature for 20 min and analysed by flow cytometry. Antibodies used were anti-
HLA class I (Biolegend), anti-HLA DR (BD Biosciences), anti-CD80 (BD Biosciences), 
anti-CD86 (BD Biosciences), anti-CD54 (BD Biosciences). 
 
3.6 Detection of FκB proteins 
5 x 106 transfected cells were lysed in 50µl cytoplasmic lysis buffer (10mM Hepes, 
1.5mM MgCl2, 10Mm KCl, 0.5mM DTT and 1% NP-40) supplemented with protease 
inhibitors (Roche) at 4°C for 30 min. The lysate was centrifuged at 160 000rcf for 1min 
at 4°C, and the supernatant extracted as the cytoplasmic fraction. The residual nucleus 
was lysed in 50µl nuclear lysis buffer (10mM Tris-HCl, 0.5mM EDTA, 250mM NaCl 
and 1% NP-40) supplemented with protease inhibitors (Roche) at 4°C for 30 min. 40µl of 
the lysate was loaded per well for evaluation by 10% glycine SDS polyacrylamide gel, 
with transfer and western blotting performed as previously described. Antibodies used 
were rabbit anti-rel A, rel B, rel C, p50 and p52 (Santa Cruz). Anti-Lamin B1 (Santa 
Cruz) and anti-actin (Santa Cruz) were used to detect the loading control for the nuclear 
and cytoplasmic fractions respectively. Densitometry analysis was performed using the 
online software GelScape. 
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3.7 Measurement of CD8
+
 T cell response 
3.7.1 Chromium release assay  
An HLA-A2 restricted cytotoxic T cell line (CTL) specific for the YLLEMLWRL 
peptide epitope of LMP1 was prepared. CD8+ cells from a healthy donor were isolated 
and stimulated with LMP1 peptide-pulsed dendritic cells in the presence of 20 IU/ml IL-2 
(Protech).  
 
On day 14, the LMP1-specific CD8+ T cells were isolated with an LMP1 tetramer. 
Briefly, the T cells were incubated with 1µl of tetramer per 1 x 106 cells at 4°C for 1h. 
This was followed by a single wash in 1×PBS to remove traces of excess tetramer and 
incubation with anti-PE microbeads (Miltenyi Biotec) at 4°C for 15min. The cells were 
isolated by magnetic activated cell sorting (Miltenyi Biotec) according to the 
manufacturer’s instructions. 
 
The isolated CD8+ T cells were restimulated was once a week and IL-2 added two times 
per week. The CTL were assayed for cytotoxicity using a chromium release assay on day 
21. Target cells were labelled with 20µCi 51Cr (Amersham) per 1 x 107 cells for 1h. The 
cells were incubated with the relevant peptide (final concentration 5µM) at 37°C for 
30min. The cells were washed and 4000 cells added to each well of a 96 well round 
bottom plate (Nunc). The cells were incubated with various ratios of CTL at 37°C for 4h. 
40µl of the supernatant was harvested from each well and transferred to a lumaplate 
(Perkin Elmer) for analysis with a TopCount NXT (Perkin Elmer). Specific lysis was 
calculated as:  
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Specific lysis(%) =
experimental chromium release - spontaneous chromium release
maximal chromium release - spontaneous chromium release
×100%  
 
3.7.2 Enzyme-linked immunospot assay (ELISPOT) for detection of IF-γ 
ELISPOT plates (eBioscience) were coated with anti-IFN-γ antibodies (Mabtech) 
overnight at 4°C. The plates were blocked with 200µl of RPMI at RT for 30min before 
incubation with 5 x 104 LMP1-specific CD8+ cells with an effector:target ratio of 10:1 at 
37°C for 16h. The plates were incubated with 100µl of biotin-conjugated anti-IFN-γ 
detection antibody (Mabtech) at RT for 2h, followed by 100µl of streptavidin-conjugated 
alkaline phosphatase (AP) (Mabtech) at RT for 1h. 50µl of 5-bromo-4-chloro-3-indolyl 
phosphate (BCIP) (Mabtech) was added for colour development and incubated for 5min 
before quenching the reaction and quantitation on an ELISPOT counter (Zeiss). All 
antibodies were diluted 1:200 and a 6-times wash with 1×PBS was included in between 
every step. 
 
3.8 Statistical analysis 
Results are expressed as mean ± SEM, where experiments are representative of more than 
one experiment. Where results are representative of one experiment, values are expressed 
as mean values of duplicates ± SD. 
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Chapter 4: RESULTS 
 
4.1 Comparison of protein sequence of WT LMP1 and PC LMP1 
The WT LMP1 and NPC LMP1 genes were amplified from the EBV-transformed B cell 
line CF986 and the well-defined NPC cell line C666 (Siu et al., 1999) respectively. The 
PCR products were sequenced and their translated protein sequences compared to 
highlight potential functional differences in the two variants. 
 
We show that there are 24 point mutations in NPC LMP1 compared to WT LMP1 (figure 
4.1). Notably, the HLA-A2 restricted epitope, YLLEMLWRL has two point mutations 
(L126F and M129I) which may impact upon its binding to the HLA-A2 molecule. The 
NPC LMP1 sequenced also carries a 10 amino acid deletion at the C-terminus, which has 


















Fig 4.1. Protein sequence alignment of WT LMP1 and PC LMP1. Multiple point 
mutations are detected (highlighted in red) in NPC LMP1. The HLA-A2 restricted 
epitope, YLLEMLWRL (highlighted in yellow) has two point mutations in NPC LMP1 
that may reduce peptide loading onto HLA-A2 molecules. 
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4.2 Expression of the WT LMP1 and PC LMP1 protein in CE-1 cells 
To set up an in-vitro system for studying the antigen presentation of LMP1, WT LMP1 
and NPC LMP1 were amplified from CF986 and C666 respectively and cloned into a 
lentiviral vector, pLenti6. WT LMP1 and NPC LMP1 were expressed in the HLA-
A*0201 positive CNE1-A2 cell line by lentiviral transduction to ensure stable expression 
of the protein. Expression of the LMP1 protein was confirmed by western blotting with 
an LMP1-specific antibody cocktail (Figure 4.2). Two bands were observed with WT 
LMP1, the lower molecular weight band being a degradation product which was shown 
to be presently previously (Yu et al., 2002). NPC LMP1 has a slightly smaller molecular 
weight than WT LMP1.  
 
Due to the significantly lower detection of NPC LMP1 by western blotting, we wanted to 
verify if this was due to a lower expression of NPC LMP1 in the transfected cells, or the 
inability of the antibody cocktail to detect specific variants of LMP1. Detection of LMP1 
transcripts by RT PCR was carried out to determine if the transcription levels of WT 
LMP1 and NPC LMP1 were similar. The mRNA transcript levels of WT LMP1 and NPC 










Fig 4.2. Detection of LMP1 expression in transfected cells by western blotting. LMP1 
was detected in CNE1-A2 cells transfected with WT LMP1 and NPC LMP1 while cells 
transfected with empty vector did not express LMP1. Lane 1: CNE1-A2 transfected with 
empty vector, lane 2: CNE1-A2 transfected with WT LMP1, lane 3: CNE1-A2 








Fig 4.3. Detection of LMP1 transcripts in transfected cells. Lane 1: CNE1-A2 
transfected with empty vector, lane 2: CNE1-A2 transfected with WT-LMP1, lane 3: 
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4.3 Detection of antigen presentation on transfected cells 
4.3.1 Detection of LMP1 peptide-HLA-A2 complexes in the transfected cells 
A murine-generated TCR-like monoclonal antibody specific for the LMP1 peptide 
epitope presented in the context of HLA-A*0201, #230, was produced using the HLA-
A*0201-LMP1 peptide monomer as immunogen. The prevalence of HLA-A*0201 is less 
than 20% in the Singapore population, as compared to HLA-A*0207, which is 50% (Ren 
et al., 1995). However, HLA-A*0201 was chosen for immunization as it had the same 
ability to bind the HLA-A2 restricted LMP1 epitope as HLA-A*0207 (fig. 4.10). #230 is 
specific for the peptide presented on HLA-A2, and binds to HLA-A2-positive C1R A2 
cells pulsed with WT LMP1 peptide, but not to C1R A2 pulsed with the HLA-A2-
restricted Influenza A matrix protein 1 (M1) peptide epitope (Figure 4.4). 
 
#230 was used to detect the amount of specific HLA-A2-LMP1 peptide complexes 
present on the transfected cells. Cell lysate from 35S-methionine-labeled transfected cells 
was incubated with #230 and immunoprecipitated with protein G-sepharose. Background 
binding of complexes was observed with the empty-vector transfected cells as #230 binds 
directly to a low level of HLA-A2. A higher level of HLA-A2-LMP1 peptide complexes 
was detected on cells transfected with WT LMP1 compared to cells transfected with NPC 







Fig 4.4. Binding specificity of #230. #230 binds to C1R A2 cells pulsed with LMP1 
peptide (red) but not to cells pulsed with M1 peptide (blue). C1R A2 cells with secondary 
antibody only (green) and C1R cells with #230 and secondary antibody (pink) were used 






      
 
      
 
      
 
Fig 4.5. Immunoprecipitation of 35S-methionine-labelled cell lysate —A higher 
amount of LMP1 peptide-HLA-A2 complexes was immunoprecipitated by the TCR-like 
antibody #230 in WT-LMP1-transfected cells relative to NPC-LMP1 transfected cells. 
Lane 1: CNE1-A2 infected with empty vector, lane 2: CNE1-A2 infected with WT-
LMP1, lane 3: CNE1-A2 infected with NPC-LMP1. Actin served as loading control. The 
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4.3.2 Expression of antigen presenting and co-stimulatory molecules on the surface 
of transfected cells 
LMP1 has been reported to influence the expression of molecules involved in antigen 
presentation, such as TAP1, HLA class I and ICAM-1. We were interested to know if 
differences in the antigen presentation of the HLA-A2-LMP1 peptide complexes were 
due to changes in the expression level of antigen presentation molecules rather than the 
endogenous processing of LMP1. TAP1 is required for loading of endogenous peptides 
onto HLA class I, HLA Class I and HLA DR present epitopes to CD8+ and CD4+ T cells 
respectively while CD80, CD86 and ICAM-1 are involved in co-stimulation. 
 
The level of TAP1 mRNA transcripts was constant for all transfected cells (Figure 4.6), 
indicating that loading of peptides onto HLA class I was consistent. There was a slight 
downregulation of HLA class I and upregulation of ICAM-1 on CNE1-A2 cells 
transfected with WT LMP1 and NPC LMP1 compared to the empty vector control 
(Figure 4.7). However, for the purpose of our research, there is no difference in 
expression of these two molecules between WT LMP1 and NPC LMP1 transfected cells. 
The surface expression of HLA-DR and the co-stimulatory molecules, CD80 and CD86 
was negligible for both the transfected cells. 
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Fig. 4.6. Level of TAP1 transcripts in transfected cells. The level of TAP1 transcripts 
was constant for all transfected cells. Lane 1: CNE1-A2 transfected with empty vector, 
lane 2: CNE1-A2 transfected with WT-LMP1, lane 3: CNE1-A2 transfected with NPC-
LMP1. Actin served as internal control to ensure consistent levels of RNA was used in 








WT LMP1 PC LMP1 






















Fig. 4.7. Surface expression of molecules involved in antigen presentation on the 
transfected CE1-A2 cells. Cells were tested for expression of (A) HLA Class I, (B) 
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4.4 Activation of FκB proteins in the transfected cells 
As NFκB signaling is also involved in antigen presentation, we were interested in 
potential activation of NFκB pathway induced by WT LMP1 and NPC LMP1, and 
whether there were any differences between the two. Cell lysate was analysed for levels 
of Rel-A, Rel-B, Rel-C, p50 and p52 in the nuclear and cytoplasmic fractions. WT LMP1 
and NPC LMP1-transfected cells showed an increase in the levels of Rel-A, Rel-B, Rel-C 
and p50 relative to the empty vector control (Figure 4.8). Actin was used as a loading 
control in the cytoplasmic fraction and to indicate minimal cytoplasmic contamination in 
the nuclear fraction. Lamin B1 was used as loading control for the nuclear fraction. The 
results show that NPC LMP1 has the same signaling capabilities as WT LMP1 despite 








   
 
   
 











Protein ∆empty vector ∆WT LMP1 ∆PC LMP1 
Rel A 85590 387451 605639 
Rel B 967743 1170196 1764822 
Rel C 21070 67531 68652 
p50 24307 94551 211805 
 
Fig. 4.8. uclear localisation of FκB proteins in the transfected cells. WT LMP1 
and NPC LMP1-transfected cells showed an increase in the levels of Rel-A, Rel-B, Rel-C 
and p50 relative to the empty vector control. NPC LMP1-transfected cells showed an 
increase in the level of Rel-C and p50 compared to WT LMP1. Densitometry analysis of 
selected proteins in nuclear fraction is shown in the table. Data shown is representative of 
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4.5 Ability of peptide epitopes from WT LMP1 and PC LMP1 to stabilise HLA-A2  
We were interested in determining if the lower presentation of NPC LMP1 was due to a 
lower binding affinity of the peptide epitope for HLA-A2. TAP-negative T2 cells were 
pulsed with the HLA-A2 restricted YLLEMLWRL peptide epitope from WT LMP1 and 
the corresponding YFLEILWRL peptide epitope from NPC LMP1. After a 6h incubation 
period, the T2 cells showed an increase in surface HLA-A2 stabilisation when pulsed 
with both peptides, compared to an irrelevant peptide control. However, the peptide 
epitope from WT LMP1 showed a significantly higher degree of stabilisation compared 
to NPC LMP1 (fig. 4.9). Therefore, an important contributing factor for the lower 
presentation of NPC LMP1 is the relatively weak ability of the peptide epitope to bind 
HLA-A2. 
 
HLA-A2 has been previously associated with an increased risk of NPC in the Chinese 
population (Lu et al., 1990).  Notably, this association was shown to be restricted to the 
HLA-A*0207 allele (Hildesheim et al., 2002). Hence, we were interested in finding out if 
there were differences in the loading of the WT LMP1 and NPC LMP1 peptide epitopes 
onto cells of different HLA-A2 subtypes. BLCLs heterozygous for HLA-A*0201, *0206 
and *0207 were pulsed with increasing concentrations of peptide and the loading of 
peptide onto the HLA-A2 molecule detected by #230 using flow cytometry. It was 
revealed that for all HLA-A2 subtypes, the WT LMP1 peptide epitope had higher levels 







Fig 4.9. Increased stabilisation of empty HLA-A2 molecules with the WT LMP1 
compared to the PC LMP1 peptide epitope. The peptide epitope from WT LMP1 
showed a greater degree of stabilisation of surface HLA-A2 on TAP-deficient T2 cells as 
compared to NPC LMP1. Data is shown as fold increase in MFI over the irrelevant 
peptide control. The results are expressed as mean±SE and are representative of seven 










Fig 4.10. Detection of peptide loading on BLCLs expressing different HLA-A2 
alleles. The WT LMP1 peptide epitope consistently shows a higher degree of loading 
than NPC LMP1 in cells expressing (A) HLA-A*0201, (B) A*0206 and (C) A*0207. 
HLA-A and HLA-B alleles of the cell lines are shown in the appendix. Results are 





4.6 Measurement of CD8
+
 T cell response  
4.6.1 Killing of peptide pulsed CE1-A2 cells by an LMP1-specific CD8
+
 T cell line 
We were interested in seeing if a difference in peptide presentation between WT LMP1 
and NPC LMP1 would translate into a functional difference in CD8+ T cell killing. 
Therefore, an LMP1-specific T cell line was set up using cells derived from a HLA-
A*0201 positive donor. CD8+ T cells were stimulated with peptide-pulsed DCs for two 
weeks before LMP1-specific T cells were positively selected with a specific tetramer. 
The percentage of CD8+tetramer+ T cells in culture increased from 1.01% to 38.0% 
following selection with the tetramer (Figure 4.11). 
 
The LMP1-specific T cell line was used on day 21 in a standard 51Cr-release assay using 
peptide-pulsed CNE1-A2 cells as targets. The specific killing of WT LMP1 peptide-
pulsed target cells was significantly higher than NPC LMP1 peptide-pulsed cells for the 
range of peptide concentrations tested (Figure 4.12). The stagnation in T cell lysis at 
10nM reflected the degree of unspecific background lysis as the cell line is made up of 
62% unspecific T cells. To further elaborate on this result, the CTL assay was performed 
using WT LMP1 and NPC LMP1-transfected CNE1-A2 cells as target. At an 
effector:target (E:T) ratio of 0.1:1, the WT LMP1-transfected cells showed a higher 










Fig 4.11. Purity of LMP1-specific CD8
+
 T cell line (A) before isolation with LMP1 
tetramer, (B) after isolation with LMP1 tetramer. The percentage of LMP1-specific T 









Fig 4.12. Specific lysis of WT LMP1 and PC LMP1 peptide-pulsed CE1-A2 cells 
by an LMP1-specific CD8
+ 
T cell line. The T cell line shows a higher killing of WT 




Fig 4.13. Specific lysis of WT LMP1 and PC LMP1-transfected CE1-A2 cells by 
an LMP1-specific CD8
+ 
T cell line. The T cell line shows a higher killing of WT LMP1-






4.6.2 ELISPOT detection of IF-γ production by stimulated LMP1-specific CD8+ T 
cells 
The LMP1-specific T cell line (Figure 4.11) was stimulated with peptide-pulsed and 
transfected CNE1-A2 cells for 16h before detection of IFN-γ by ELISPOT. At an 
effector:target ratio of 10:1, a larger proportion of T cells produced IFN-γ when 
stimulated with WT LMP1 peptide-pulsed CNE1-A2 cells compared to those pulsed with 
NPC LMP1 peptide (Figure 4.14). A similar trend was shown using transfected cells as 
targets (Figure 4.15). The results of this ELISPOT assay show that significantly less 
CD8+ T cells are activated when NPC LMP1 peptide-pulsed targets are used, and that this 
trend also holds true for cells presenting endogenously processed NPC LMP1. A lower 
E:T ratio was used in this experiment as the T cell line had been grown for an extended 
period of time, resulting in higher specificity and a requirement for lower T cell numbers 




Fig 4.14. IF-γ production by an LMP1-specific CD8
+ 
T cell line when stimulated 
with WT LMP1 and PC LMP1 peptide-pulsed CE1-A2 cells. The T cell line 
shows a higher production of IFN-γ when stimulated with WT LMP1 peptide-pulsed cells 
compared to NPC LMP1 as measured by ELISPOT. Results are expressed as mean±SE 
and are representative of two independent experiments. *p<0.01 
 
  
Fig 4.15. IF-γ production by an LMP1-specific CD8
+ 
T cell line when stimulated 
with WT LMP1 and PC LMP1-transfected CE1-A2 cells. The T cell line shows a 
higher production of IFN-γ when stimulated with WT LMP1-transfected cells compared 
to NPC LMP1 as measured by ELISPOT. Results are expressed as mean±SE and are 






Chapter 5: DISCUSSIO  
 
5.1 Summary 
In this study, we have shown that antigen presentation of NPC LMP1 (associated with 
NPC tumour biopsies) is impaired compared to WT LMP1 (associated with B 
lymphocytes of healthy EBV carriers) due to differences in protein sequence. The 
impaired presentation of the HLA-A2-restricted YLLEMLWRL epitope was primarily 
due to two point mutations in the epitope of NPC LMP1 that reduced binding to HLA-
A2.  As a result, LMP1-specific CD8+ T cells had reduced specific killing and IFN-γ 
production upon stimulation with NPC LMP1 peptide-pulsed target cells. The results of 
this study point to a possible mechanism whereby EBV strains containing the NPC LMP1 
variant is able to evade the immune response, resulting in the current observation of mass 
infiltration of unresponsive CD8+ T cells into NPC biopsies. 
 
5.2 Differences in protein sequence between WT LMP1 and PC LMP1 
The initial suggestion that there may be variations in LMP1 sequences that affect antigen 
presentation was derived from the observation that healthy carriers of EBV can mount an 
ex-vivo response against LMP1 while this response was rarely seen in NPC patients 
(Khanna et al., 1998; Li et al., 2007). Interestingly, it was noted that there was substantial 
infiltration of lymphocytes into the well-vascularised NPC tumour (Li et al., 2007), 
although it is not known if the lymphocytes were mounting any form of attack against 
tumour cells. Since then, six variants of LMP1 have been described relative to the 
prototypic WT LMP1 strain (Bernado et al., 2006). 
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An initial alignment of the translated nucleotide sequence between WT LMP1 and NPC 
LMP1 showed that there were numerous amino acid differences between the two LMP1 
variants, notably a two amino acid-change in the HLA-A2-restricted epitope 
YLLEMLWRL. NPC LMP1 has been described previously to differ from the prototypic 
WT LMP1 in the YLLEMLWRL epitope and also in a 10 amino acid-deletion between 
CTAR1 and CTAR2 (Edwards et al., 1999). Several studies have indicated that this 
variant of LMP1 is strongly associated with NPC risk, but was rarely present in healthy B 
cell carriers (Cheung et al., 1999; Lin et al., 2004). It was postulated that the mutations in 
NPC LMP1 resulted in epitope loss and reduced antigen presentation although no attempt 
has been made to directly compare the surface levels of HLA-peptide complexes on the 
cell surface. 
 
To address this issue, we expressed the WT LMP1 and NPC LMP1 gene in the EBV-
negative CNE1-A2 cell line and subsequently carried out assays to determine the level of 
presentation of these two LMP1 variants. It was noted that although both LMP1 variants 
were expressed in the cells, the detection of NPC LMP1 by western blotting was 
substantially lower than WT LMP1. However, RT PCR analysis revealed that the levels 
of mRNA transcripts were in fact similar for both WT LMP1 and NPC LMP1. 
Interestingly, a similar phenomenon was also observed in NPC patient biopsies. Studies 
have detected LMP1 in 80-90% of cases by RT PCR (Brooks et al., 1992; Lin et al., 
2001) but only in 20-60% of cases by immunostaining (Sarac et al., 2001; Murono et al., 
1999; Chen et al., 2001). 
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Two reasons could account for this observation: firstly, the anti-LMP1 antibody cocktail 
used for immunodetection was not optimal for detection of NPC LMP1 as the antibodies 
were primarily directed against the C terminal region of WT LMP11. Our sequence 
alignment of WT LMP1 and NPC LMP1 showed that there were substantial mutations in 
the C-terminus of NPC LMP1, including the 10 amino-acid deletion. These sequence 
differences could destroy the recognition epitope and impair binding of the antibodies, 
thus resulting in a lower detection of NPC LMP1. 
 
The second reason for the lower detection of protein expression could be due to inherent 
instability of the NPC LMP1 protein structure. Given that there are point mutations in 
NPC LMP1, the protein may be directed to the wrong compartment or misfold during the 
nascent chaperoning process in the ER. The targeting of a protein sequence to the ER for 
synthesis and folding is dictated by the first 15-30 amino acids of the nascent polypeptide 
chain and typically consists of a large proportion of hydrophobic amino acids. The 
protein sequence alignment shows that there are four point mutations in the first 30 amino 
acids in the N-terminus of NPC LMP1. Two of the mutations involve a change to an 
amino acid of the same charge while the other two result in a change from a basic amino 
acid to a hydrophobic one (R13P and R14L). Since there is no decrease in the proportion 
of hydrophobic amino acids, targeting to the ER is not likely to be affected. On the other 
hand, it is not known if the protein is misfolded and hence non-functional. We speculate 
that this is unlikely based on the results of subsequent functional assays, since NPC 
LMP1 appears to have the same level of activation of NFκB proteins. Secondly, if NPC 
                                                 
1 Imgenex datasheet for CS1-4 cocktail (http://www.imgenex.com/antibody_details.php?catalog=IMG-
80130) 
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LMP1 was misfolded, we would expect a higher level of antigen presentation due to the 
increased formation of defective ribosomal products (DRiPs) (Yewdell et al., 1996), but 
this was not observed in our study. The plausibility of misfolded NPC LMP1 could be 
addressed using a pulse-chase assay. However, this assay would be subject to the 
availability of a good quality anti-LMP1 antibody that has similar affinity for both WT 
LMP1 and NPC LMP1. 
 
5.3 Impaired presentation of the YLLEMLWRL epitope is observed with PC 
LMP1 due to poor peptide binding to HLA-A2 
Four HLA-A2-restricted LMP1 epitopes have been characterised (Khanna et al., 1998; 
Edwards et al., 2001). The epitope YLLEMLWRL is of great interest because it is the 
only one of these four epitopes that appears to vary in sequence depending on the 
geographical location of the infected individual (Edwards et al., 2001; Lin et al., 2001).  
 
In our study, the detection of HLA A2-peptide complexes on the surface of the NPC 
LMP1-transfected cells was lower than that of WT LMP1-transfected cells. It was 
suspected that this was due to a lower affinity of the peptide epitope in NPC LMP1 for 
the HLA-A2 molecule. In NPC LMP1, the peptide epitope has been mutated in two 
positions, notably a change in the second position from leucine to phenylalanine. Peptide 
epitopes are anchored to the peptide binding groove of HLA-A2 by residues in the second 
and ninth position, resulting in HLA-A2-restricted epitopes invariably bearing the amino 
acid leucine in position two (Parker et al., 1992; Ruppert et al., 1993; Bouvier and Wiley, 
1994). Since the epitope of NPC LMP1 has been mutated at position two, it is likely that 
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binding to HLA-A2 will be affected. Moreover, it appears that even if the peptide is able 
to bind HLA-A2, it will subtly change positioning of central residues in the HLA-peptide 
complex such that TCR binding is affected (Sharma et al., 2001). 
To address this question, we compared the relative abilities of the peptide epitopes from 
WT LMP1 and NPC LMP1 to bind to and stabilise empty HLA-A2 molecules. The 
peptide epitope from NPC LMP1 was able to bind to HLA-A2 molecules, but to a 
significantly lesser extent than WT LMP1. This observation was also made by Khanna et 
al. (1998) when they compared the binding of different LMP1 peptide epitopes to HLA-
A2. Moreover, the NPC LMP1 epitope clearly showed poorer binding than WT LMP1 
when tested on several HLA-A2 subtypes (HLA-A*0201, HLA-A*0206, HLA-A*0207). 
Interestingly, the difference in binding between the WT LMP1 and NPC LMP1 epitope to 
HLA-A*0207, which is associated with an increased risk of NPC (Hildesheim et al., 
2002), appeared less at high peptide concentrations (10 000nM and 100 000nM). 
Nevertheless, this level of available peptide for antigen presentation is not relevant 
physiologically as this gives 1×105 HLA A2-peptide complexes per cell while natural 
antigen processing only generates approximately 1×103 - 1×104 complexes (Cohen et al., 
2003). Furthermore, when HLA-A*0207-expressing target cells were pulsed with 
saturating amounts of NPC LMP1 epitope, there was no increase in specific lysis by an 
LMP1-specific CD8+ T cell line, relative to HLA-A*0201-expressing target cells 
(Appendix).  
 
5.4 PC LMP1 does not affect the expression of antigen presenting molecules 
relative to WT LMP1 
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To ensure that the lower presentation of NPC LMP1 was not a result of downregulation 
of antigen presenting molecules, we compared the expression level of HLA class I and 
TAP1 on the transfected cells. The expression levels of HLA class I and TAP1 were 
similar for both transfected cells, indicating that the poorer presentation of NPC LMP1 
was primarily due to poorer epitope binding to HLA class I. In line with our results, 
Khanna et al. (1998) also previously studied the antigen processing capacity of NPC cells 
and found that there was no impairment of TAP or the immunoproteasome. 
 
However, what was surprising was that WT LMP1 and NPC LMP1-transfected cells 
downregulated HLA class I to a similar extent compared to the empty vector control. WT 
LMP1 has been shown in previous studies to upregulate HLA class I on B cells (Pai et 
al., 2002), therefore our finding is a novel one. An NPC cell line was used in our work 
for a more physiologically relevant comparison of antigen presentation in NPC and the 
difference in cell type used could have resulted in different signaling responses to LMP1. 
Downregulation of HLA class I is a common strategy used by several viruses in immune 
evasion and it is not unexpected that EBV employs the same tactic through LMP1 
signaling.  In this regard, Sengupta et al. (2006) have shown a strong correlation between 
EBV gene expression and HLA class I downregulation.  
 
In this study, we noted an upregulation of ICAM-1 on the WT LMP1 and NPC LMP1-
transfected cells. This effect has been previously reported in the expression of LMP1 in 
Jurkat cells (Mehl et al., 2001). 69% of LMP1-positive NPC tumour cells show increased 
ICAM-1 expression (Li et al., 2007), indicating that ICAM-1 is important for tumour 
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growth and could be induced by LMP1. Moreover, increased soluble ICAM-1 in the 
serum of NPC patients has been associated with metastasis and ICAM-1 is being 
considered as a biomarker for clinical prognosis (Liao et al., 2008).  
 
It was clear from our observations that NPC LMP1 appeared to have the same effects as 
WT LMP1 on the expression of specific immune molecules, indicating that it has not lost 
its signaling capacity as a result of mutations in protein sequence. 
 
5.5 Signaling capability of PC LMP1 
Since WT LMP1 and NPC LMP1 had similar effects on HLA class I and ICAM-1 
expression, these two LMP1 variants may have similar signaling activity. Indeed, most of 
the point mutations in NPC LMP1 do not fall within the LMP1 signaling region CTAR1, 
with the exception of G212S. However, CTAR2 harbours more significant mutations, 
including a two amino acid deletion and a point mutation S366T. CTAR1 recruits TRAFs 
1, 2, 3 and 5 (Devergne et al., 1996; Miller et al., 1998) to activate the noncanonical 
NFκB signaling pathway while CTAR2 binds TRADDs to activate the canonical NFκB 
signaling pathway (Izumi and Kieff, 1997; Soni et al., 2007).  
 
Western blotting was carried out to determine the level of specific NFκB proteins present 
in the nucleus and cytoplasm of the transfected cells. Increased nuclear levels of rel-A, 
rel-B, rel-C and p50 were observed in the LMP1-transfected cells. This is similar to 
observations from various groups, which reported increased activation of rel-A, rel-B and 
p50 by LMP1 in epithelial cells (Paine et al., 1995; Miller et al., 1998). 
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The levels of rel-C were slightly elevated in both WT LMP1 and NPC LMP1-transfected 
cells. Rel-C was previously reported to be upregulated in murine lymphomas (Thornburg 
et al., 2006) and also in other cancer cell types such as pancreatic cancer cells (Chandler 
et al. 2004). This is the first report of an upregulation of rel-C in NPC cells. Notably, rel-
C can also form heterodimers with p50 to induce cell growth and proliferation through 
the myc pathway (Gilmore et al., 2004). From the results of this study, it appears that 
NPC LMP1 may have the same oncogenic potential as WT LMP1 despite have acquired 
a number of mutations. Previous studies have indicated that the ten amino acid deletion in 
NPC LMP1 augmented its transforming ability in Balb/3T3 cells (Li et al., 1996). 
However, when WT LMP1 and NPC LMP1 were expressed in primary B cells, no 
increase in proliferation or decrease in apoptosis was seen in the transfected B cells 
(results not shown), indicating that the proposed transforming ability is probably 
augmented by several other EBV-expressed proteins such as EBNA2 (Dirmeier et al., 
2005), LMP2A (Caldwell et al., 1998) and viral IL-10 (Irons et al., 2008).  
 
5.6 Modulation of LMP1-specific CD8
+
 T cell-mediated immunity 
CD8+ T cells are essential for controlling the proliferation of infected cells in healthy 
EBV carriers (Levine et al., 1994). As EBV is able to modulate antigen presentation via 
several mechanisms, the virus is able to persist in a quiescent state within an infected 
host, particularly in malignancies such as NPC. One of the mechanisms by which EBV 
avoids CD8+ T cell-mediated immunity is described in our study as the development of 
mutations in the HLA-A2-restricted epitope of LMP1, resulting in reducing HLA class I 
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loading and subsequent poor presentation. Hence, when the NPC LMP1 peptide epitope 
was loaded on CNE1-A2 target cells, killing by an LMP1-specific CD8+ T cell line was 
dramatically reduced compared to target cells loaded with the WT LMP1 peptide epitope. 
This trend was also shown using WT LMP1 and NPC LMP1-transfected cells as targets. 
Expanding on this observation, a study by Trivedi et al. (2000) showed that 
immunocompetent mice inoculated with NPC LMP1-transfected cells had lower numbers 
of leukocytes infiltrating the tumour compared to those inoculated with WT LMP1-
transfected cells. This could indicate that the antigen presentation of NPC LMP1 is very 
much reduced, therefore resulting in a suboptimal CD8+ T cell response. 
 
IFN-γ production by the T cells was also reduced in an ELISPOT assay, indicating that a 
smaller proportion of T cells were activated by the target cells. Interestingly, T cells 
stimulated by NPC LMP1-transfected target cells appeared to produce even less IFN-γ 
than the empty vector control. This observation mirrored that of a separate study that 
isolated LMP1-specific CD8+ T cells from NPC tumour sites but found that they were not 
cytotoxic and unable to produce IFN-γ upon stimulation (Li et al., 2007). It is possible 
that NPC LMP1 induces the production of cytokines that has an inhibitory effect on the 
immune system (Pai et al., 2007).  
 
It was noted that the difference in IFN-γ production was much lower in the LMP1-
transfected cells compared to the LMP1 peptide epitope-pulsed cells. This could be due 
to the lower amount of endogenous peptide processed and presented in the transfected 
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cells. It could also be attributed to the downregulation of HLA class I induced by WT 
LMP1 and NPC LMP1 (fig. 4.7) that resulted in reduced presentation of epitopes. 
 
5.7 Implications of this study 
Current treatment for NPC does not have a high success rate and is often accompanied by 
many side effects (Mould et al., 2002). Since NPC is a virus-associated cancer, 
researchers have actively considered immunotherapy as a future treatment option. 
Examples of NPC-based immunotherapy in the pipeline include peptide vaccines and 
adoptive T cell transfer. The results of this study suggest that identifying the relevant 
antigen and epitope is essential for the development of effective immunotherapy for NPC 
treatment.  
 
Peptide vaccines are the main form of immunisation considered because many EBV-
expressed proteins such as LMP1 are oncogenic, making the full-length proteins unsafe 
for usage in a vaccine. To this end, peptide epitopes have been identified from LMP1 
using HLA-A2 transgenic mice (Bharadwaj et al., 2001). However, because specific 
variants of LMP1 appear to dominate different geographical locations (Duraiswamy et 
al., 2003), the sequence of the peptide epitope needs to be catered to different ethnic 
groups before it is effective. In our study, we have shown that in Southeast Asia and 
China, where the NPC LMP1 variant dominates, immunisation with the YLLEMLWRL 
epitope of LMP1 is not likely to be useful because it will not be presented well on 
infected cells in the event of EBV infection. Therefore, the remaining three HLA-A2-
restricted epitopes of LMP1 would be a better choice for an EBV vaccine cocktail.  
 56 
 
Adoptive T cell transfer has been shown to alleviate EBV-associated lymphoproliferative 
diseases in immunocompromised patients (Heslop et al., 1996; Gustafsson et al., 1999). 
LMP1 is considered a prime target for adoptive T cell therapy in NPC because healthy 
carriers can make a CD8+ T cell response to HLA-A2-restricted epitopes (Khanna et al., 
1998). However, the results of this study show that NPC LMP1 has impaired presentation 
of the YLLEMLWRL epitope, therefore, CD8+ T expanded ex vivo with this epitope are 
not likely to kill LMP1-expressing NPC cells. Moreover, based on the ELISPOT data in 
this study, and the results of several other publications (Pai et al., 2007; Li et al., 2007), it 
is suggested that the cytotoxicity of CD8+ T cells is downmodulated in the tumour 
microenvironment. Taken together, adoptive T cell therapy is not an effective treatment 
option for NPC, although it was successful in controlling other EBV-associated 
malignancies. 
 
This study has provided an example of how immune selection pressure can lead to 
mutations in viral antigens that aid their immune evasion. This phenomenon is not 
restricted to EBV, but is also frequently seen in other viruses, such as the measles virus 
(van Els et al., 2000) and Hepatitis C virus (Keck et al., 2008). The CD8+ response to 
LMP1 is often restricted through HLA-A2 alleles (Meij et al .2002), thus making an 
HLA-A2-restricted epitope a prime target for mutation. However, it is surprising that this 
mutation is predominant in China and Southeast Asia where the HLA-A2 frequency is 
20%, as compared to 55% in the Caucasian population. We initially speculated that the 
WT LMP1 epitope may be better presented on the HLA-A*0207 allele, which is more 
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common in Chinese populations, leading to increased immune selection pressure on the 
virus. Nonetheless, our study showed that the binding of the WT LMP1 epitope to HLA-
A*0207 was not much higher than that of HLA-A*0201 or HLA-A*0206, indicating that 
this was not a factor driving the increased mutations in LMP1. Despite this, we did not 
exclude the possibility of linkage of genes to the HLA-A*0207 allele that could modify 
antigen presentation. 
 
5.8 Limitations of this study and future work 
This study has focused on one of the known CD8+ epitopes of LMP1. NPC LMP1 can be 
presented on other HLA genotypes but many of the amino acid substitutions in NPC 
LMP1 fall within known or predicted epitopes of other HLA restriction (Edwards et al., 
2001). An elaboration of this study would be to compare the presentation of the other 
epitopes in the WT LMP1 and NPC LMP1-transfected cells. The combined results would 
provide more insight into which epitopes in LMP1 are suitable for a vaccination cocktail. 
 
A series of experiments involving RT PCR were performed to determine the expression 
level of the transfected LMP1 and endogenous TAP in the cells. However, the result is 
qualitative and would be better supplemented with real time PCR data. This was not 
performed due to time constraints. 
 
We have also not addressed the exact binding sites of the antibody #230, which was used 
for detection of the HLA-peptide complexes. This is an important issue as there are 
differences in sequence between the peptide epitope of WT LMP1 and NPC LMP1 that 
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could potentially interfere with the binding of #230. However, since the results of the 
MHC stabilisation assay correlated to the detection of complexes by #230, we are 
confident that the impaired binding of the NPC LMP1 epitope to HLA A2 explained the 
reduction in antibody recognition. Currently, we are in the process of mapping the 
epitope of #230 for a more definitive answer. 
 
5.9 Conclusion 
In this study, we show that an NPC-associated variant of LMP1 has multiple mutations 
that result in loss of an HLA-A2-restricted epitope YLLEMLWRL, leading to a lack of 
CD8+ T cell response. Our observations indicate that vaccination and immunotherapy for 
NPC should avoid the use of this epitope, particularly in endemic countries such as 
Southeast Asia and China. On a bigger perspective, studies involving potential vaccine 
strategies need to take into consideration variation in target protein sequences to ensure 
that an effective T cell response can be made for all variants of a virus. 
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Chapter 7: APPEDIX 
 
 
Fig 7.1. Comparison of specific lysis by LMP1-specific CD8
+
 T cell line on HLA-
A*0201 and HLA-A*0207-expressing target cells. There was no increase in specific 
lysis when HLA-A*0207-expressing target cells were pulsed with saturating levels of 




Fig. 7.2. Expression levels of HLA-A2 on the surface of the BLCLs. All BLCLs tested 
expressed a reasonable level of HLA-A2 as tested in flow cytometry. 
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Table 7.1. Sequences of primers used in study 
 
Primer name Primer sequence (5’3’) 
WT LMP1 forward primer CACCATGGAACACGACCTTGAGAG 
NPC LMP1 forward primer CACCATGGAACGCGACCTTGAGAG 
LMP1 reverse primer TTAGTCATAGTAGCTTAGCTGAACTGG 
TAP1 forward primer GGGATCCTGTGACCATTGGGGCTGTAAGC 
TAP1 reverse primer CTCTAGAGGTTATTCTGGAGCATCTGCAGGAG 
β actin forward primer GCTCCGGCATGTGCAA 
β actin reverse primer AGGATCTTCATGAGGTAGT 
 
Table 7.2 HLA-A and HLA-B alleles of BLCLs used in fig. 4.10 
 
Cell line HLA-A HLA-B 
A (CF1018) 0201, 0203 1502, 3802 
B (CM306) 0206, 3303 1502, 5801 
C (CF498) 0207, 2402 2704, 4601 
 
